After falling 17 per cent since the start of the year to its March lows, the stock of the country’s largest pharmaceutical ...

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...